CL2015002121A1 - Modulares de receptores nmda de espiro-lactama y sus usos. - Google Patents

Modulares de receptores nmda de espiro-lactama y sus usos.

Info

Publication number
CL2015002121A1
CL2015002121A1 CL2015002121A CL2015002121A CL2015002121A1 CL 2015002121 A1 CL2015002121 A1 CL 2015002121A1 CL 2015002121 A CL2015002121 A CL 2015002121A CL 2015002121 A CL2015002121 A CL 2015002121A CL 2015002121 A1 CL2015002121 A1 CL 2015002121A1
Authority
CL
Chile
Prior art keywords
spiro
modular
nmda receptors
lactam nmda
lactam
Prior art date
Application number
CL2015002121A
Other languages
English (en)
Spanish (es)
Inventor
M Amin Khan
John A Lowe Iii
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of CL2015002121A1 publication Critical patent/CL2015002121A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
CL2015002121A 2013-01-29 2015-07-29 Modulares de receptores nmda de espiro-lactama y sus usos. CL2015002121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361757903P 2013-01-29 2013-01-29

Publications (1)

Publication Number Publication Date
CL2015002121A1 true CL2015002121A1 (es) 2015-12-04

Family

ID=50071821

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015002121A CL2015002121A1 (es) 2013-01-29 2015-07-29 Modulares de receptores nmda de espiro-lactama y sus usos.
CL2015002125A CL2015002125A1 (es) 2013-01-29 2015-07-29 Moduladores de receptores nmda de espiro-lactama y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2015002125A CL2015002125A1 (es) 2013-01-29 2015-07-29 Moduladores de receptores nmda de espiro-lactama y sus usos.

Country Status (27)

Country Link
US (9) US9512134B2 (cg-RX-API-DMAC10.html)
EP (2) EP3514158B1 (cg-RX-API-DMAC10.html)
JP (2) JP2016506958A (cg-RX-API-DMAC10.html)
KR (1) KR102280616B1 (cg-RX-API-DMAC10.html)
CN (1) CN105229011B (cg-RX-API-DMAC10.html)
AU (1) AU2014212484B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015018087B1 (cg-RX-API-DMAC10.html)
CA (1) CA2898861C (cg-RX-API-DMAC10.html)
CL (2) CL2015002121A1 (cg-RX-API-DMAC10.html)
CY (1) CY1121675T1 (cg-RX-API-DMAC10.html)
DK (1) DK2951183T3 (cg-RX-API-DMAC10.html)
EA (1) EA032649B1 (cg-RX-API-DMAC10.html)
ES (2) ES2734405T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20190613T1 (cg-RX-API-DMAC10.html)
HU (1) HUE043843T2 (cg-RX-API-DMAC10.html)
IL (1) IL240163B (cg-RX-API-DMAC10.html)
LT (2) LT2951183T (cg-RX-API-DMAC10.html)
MX (1) MX2015009786A (cg-RX-API-DMAC10.html)
MY (1) MY188450A (cg-RX-API-DMAC10.html)
PE (1) PE20151416A1 (cg-RX-API-DMAC10.html)
PH (1) PH12015501601B1 (cg-RX-API-DMAC10.html)
PL (1) PL2951183T3 (cg-RX-API-DMAC10.html)
PT (2) PT3514158T (cg-RX-API-DMAC10.html)
SG (1) SG11201505860XA (cg-RX-API-DMAC10.html)
SI (2) SI2951183T1 (cg-RX-API-DMAC10.html)
TR (1) TR201908596T4 (cg-RX-API-DMAC10.html)
WO (1) WO2014120783A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
EP2951185B1 (en) 2013-01-29 2016-12-21 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
HRP20190613T1 (hr) 2013-01-29 2019-06-28 Aptinyx Inc. Spiro-laktam modulatori nmda receptora i njihove uporabe
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
BR112015018089B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor de nmda de espiro-lactama, composição farmacêutica os compreendendo e uso dos mesmos
CN109415372B (zh) * 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
MX388786B (es) 2016-08-01 2025-03-20 Aptinyx Inc Moduladores nmda espiro-lactam y métodos de uso de los mismos.
IL286107B2 (en) * 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
WO2019152685A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and methods of using same
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2019152688A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3089559A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12162883B2 (en) 2019-04-26 2024-12-10 Merck Sharp & Dohme Llc Process for the preparation of intermediates useful for making (2S,5R)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
AU2020304001A1 (en) * 2019-06-24 2022-01-27 Naurex Inc. Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them
CN120004904A (zh) 2019-06-24 2025-05-16 诺雷克斯股份有限公司 生产二氮杂螺内酰胺化合物的方法和中间体
WO2021021996A1 (en) * 2019-08-01 2021-02-04 Aptinyx Inc. Methods of treating disorders associated with elevated levels of antibodies that interact with the nmda receptor
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (en) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthesis of beta-lactam
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
TR199802537T2 (xx) 1996-06-07 1999-03-22 Zeneca Limited Peptit t�revleri.
US5959075A (en) 1996-08-02 1999-09-28 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000027790A1 (en) 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
EP1255854A2 (en) 2000-02-01 2002-11-13 Agy Therapeutics, Inc. Interaction of nmda receptor with protein tyrosine phosphatase
JP2001261679A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
AU2001268467A1 (en) 2000-06-14 2001-12-24 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
EP1296999A2 (en) 2000-06-22 2003-04-02 NYXIS NeuroTherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
AU2002236608A1 (en) 2000-12-14 2002-06-24 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
US20030065138A1 (en) 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
EP1519939B9 (en) 2002-07-05 2011-04-06 Targacept, Inc. N-aryl diazaspirocyclic compounds and methods of preparation and use thereof
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1776362A1 (en) 2003-07-18 2007-04-25 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
WO2005014797A2 (en) 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2005047286A1 (ja) 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
BRPI0418375A (pt) 2004-01-08 2007-05-22 Hoffmann La Roche derivados de diaza-espiropiperidina
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
CN101090902B (zh) 2004-10-13 2013-05-29 默沙东公司 Cgrp受体拮抗剂
PT1868614E (pt) 2005-03-24 2012-11-23 Univ Emory Regime de dosagem para o tratamento de uma lesão cerebral traumática com progesterona
AU2006282942B2 (en) 2005-08-26 2012-07-26 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US7884080B2 (en) 2006-09-15 2011-02-08 Schering Plough Corporation Azetidinone derivatives and methods of use thereof
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
EP2257644B1 (en) 2008-02-20 2015-06-24 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis of autism
CA2728727C (en) 2008-06-24 2018-01-23 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
RU2011102523A (ru) 2008-06-27 2012-08-10 Ньюросерч А/С (DK) Новые производные тетраметил-замещенного пиперидина и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов
EP2323981B1 (en) 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
WO2011044089A2 (en) 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US8871208B2 (en) 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
ES2706063T3 (es) 2010-02-11 2019-03-27 Univ Northwestern Agonistas del receptor de NMDA y usos del mismo
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
CN102267995A (zh) 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
AR082633A1 (es) 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2012125598A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
KR20180095096A (ko) 2011-04-27 2018-08-24 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
WO2013001448A1 (en) 2011-06-27 2013-01-03 Koninklijke Philips Electronics N.V. Ultrasound transducer assembly and method of manufacturing the same
PL3009431T3 (pl) 2011-07-27 2018-02-28 Astrazeneca Ab Pochodne 2-(2,4,5-podstawionej-anilino) pirymidyny jako modulatory egfr użyteczne do leczenia nowotworu
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EP2951185B1 (en) 2013-01-29 2016-12-21 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
HRP20190613T1 (hr) 2013-01-29 2019-06-28 Aptinyx Inc. Spiro-laktam modulatori nmda receptora i njihove uporabe
BR112015018089B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor de nmda de espiro-lactama, composição farmacêutica os compreendendo e uso dos mesmos
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
GB201416346D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109415372B (zh) 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
MX388786B (es) 2016-08-01 2025-03-20 Aptinyx Inc Moduladores nmda espiro-lactam y métodos de uso de los mismos.
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
CA3089559A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20210308101A1 (en) 2019-11-11 2021-10-07 Aptinyx Inc. Methods of treating fibromyalgia
CA3161742A1 (en) 2019-12-04 2021-06-10 Aptinyx Inc. Methods of treating cognitive impairment associated with neurodegenerative disease

Also Published As

Publication number Publication date
MY188450A (en) 2021-12-09
MX2015009786A (es) 2015-12-11
LT3514158T (lt) 2023-02-10
CN105229011B (zh) 2018-02-06
ES2935352T3 (es) 2023-03-06
HRP20190613T1 (hr) 2019-06-28
EA201591401A1 (ru) 2018-01-31
AU2014212484A1 (en) 2015-07-30
WO2014120783A1 (en) 2014-08-07
US20220151992A1 (en) 2022-05-19
IL240163A0 (en) 2015-09-24
SI3514158T1 (sl) 2023-03-31
CY1121675T1 (el) 2020-07-31
PL2951183T3 (pl) 2019-08-30
IL240163B (en) 2020-02-27
US11077094B2 (en) 2021-08-03
JP2016506958A (ja) 2016-03-07
EP2951183B1 (en) 2019-03-13
BR112015018087A8 (pt) 2021-06-22
SI2951183T1 (sl) 2019-07-31
JP2019019133A (ja) 2019-02-07
EA032649B1 (ru) 2019-06-28
EP3514158A1 (en) 2019-07-24
KR102280616B1 (ko) 2021-07-21
HRP20221545T1 (hr) 2023-03-03
US20170231956A1 (en) 2017-08-17
HK1218417A1 (en) 2017-02-17
CA2898861C (en) 2021-07-20
CN105229011A (zh) 2016-01-06
US20160368926A1 (en) 2016-12-22
US10441572B2 (en) 2019-10-15
PE20151416A1 (es) 2015-10-10
US9512134B2 (en) 2016-12-06
US20200206189A1 (en) 2020-07-02
EP2951183A1 (en) 2015-12-09
US9504670B2 (en) 2016-11-29
US10052308B2 (en) 2018-08-21
EP3514158B1 (en) 2022-10-12
US20160122359A1 (en) 2016-05-05
BR112015018087B1 (pt) 2022-09-20
US10441571B2 (en) 2019-10-15
JP6564513B2 (ja) 2019-08-21
US20250186392A1 (en) 2025-06-12
SG11201505860XA (en) 2015-08-28
NZ709870A (en) 2020-09-25
PH12015501601B1 (en) 2019-09-18
HUE043843T2 (hu) 2019-09-30
BR112015018087A2 (pt) 2017-07-18
CL2015002125A1 (es) 2015-12-04
US9579304B2 (en) 2017-02-28
US20180250267A1 (en) 2018-09-06
AU2014212484B2 (en) 2018-01-04
CA2898861A1 (en) 2014-08-07
ES2734405T3 (es) 2019-12-05
US20160289240A1 (en) 2016-10-06
PT3514158T (pt) 2023-01-13
KR20150110790A (ko) 2015-10-02
DK2951183T3 (da) 2019-06-03
TR201908596T4 (tr) 2019-07-22
PH12015501601A1 (en) 2015-10-19
PT2951183T (pt) 2019-06-17
US20180250268A1 (en) 2018-09-06
LT2951183T (lt) 2019-05-27
US12167998B2 (en) 2024-12-17

Similar Documents

Publication Publication Date Title
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2015002122A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CL2017003205A1 (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CL2018000883A1 (es) Moduladores del receptor x farnesoide
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
MX2017014375A (es) Moduladores del ccr2.
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2015002124A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
CL2016001763A1 (es) Antagonistas selectivos de nr2b
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
UY35750A (es) Moduladores octahidro-ciclopenta[c] pirrol negativos de nr2b